Previous 10 | Next 10 |
Summary Interim results from the phase 2 CALLIPER study using IMU-838 for treatment of patients with Progressive MS are expected in the 2nd half of 2023; topline results are end of 2024. Final results from the phase 3 ENSURE study, using IMU-838 for the treatment of patients with relaps...
Immunic ( NASDAQ: IMUX ) shares climbed ~14% after Wedbush Securities launched coverage on the clinical-stage biotech citing “best-in-class potential” for the company’s lead asset IMU-838. The analyst Andreas Argyrides argues that IMU-838, which is undergoing ...
Immunic to Participate in Scientific and Investor Conferences in February PR Newswire NEW YORK , Jan. 25, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapie...
Summary Today, we circle back on a small developmental firm called Immunic for the first time since July 2020. The company has suffered some trial setbacks since we last looked at it, but its primary drug candidate appears to have significant potential to treat MS. An investment ana...
Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug's Neuroprotective Potential PR Newswire – Data Show Encouraging Signals for Vidofludimus Calcium for Preventing or Delaying...
Immunic to Participate in Investor and Scientific Conferences in November and December PR Newswire NEW YORK , Nov. 10, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective ora...
Immunic, Inc. (IMUX) Q3 2022 Earnings Conference Call November 03, 2022, 08:00 AM ET Company Participants Jessica Breu - Head, IR and Communications Daniel Vitt - CEO and President Glenn Whaley - CFO Andreas Muehler - Chief Medical Officer Conference Ca...
Immunic, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update PR Newswire – $72.8 Million in Cash and Cash Equivalents as of September 30, 2022 , Plus $56.4 Million of Net Cash Raised in October 2022 Expected to Fun...
Immunic ( NASDAQ: IMUX ) is scheduled to announce Q3 earnings results on Thursday, November 3rd, before market open. The consensus EPS Estimate is -$0.69 Over the last 3 months, EPS estimates have seen 3 upward revisions and 1 downward. For further details se...
Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update PR Newswire – Webcast to be Held at 8:00 am ET on November 3, 2022 – NEW YORK , Oct. 27, 2022 /PRNewswir...
News, Short Squeeze, Breakout and More Instantly...
Immunic Appoints Jason Tardio as Chief Operating Officer and President PR Newswire – Former Novartis and Biogen Executive Brings Extensive Multiple Sclerosis Drug Commercialization Experience to Immunic – – Werner Gladdines, Current Vice President,...
--News Direct-- Immunic Inc CEO Daniel Vitt joined Steve Darling from Proactive to discuss the ongoing challenges and recent developments in treating multiple sclerosis (MS). This interview took place in conjunction with World MS Day, a day dedicated to raising global awareness about this...
Immunic to Participate in Industry and Scientific Conferences in June PR Newswire NEW YORK , May 28, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule thera...